ODTX · Odyssey Therapeutics, Inc.

Odyssey Therapeutics operates at the intersection of immunology and AI-enabled drug discovery, focusing exclusively on upstream innate immune targets — notably RIPK2, SLC15A4, TNFR2, TSLP/IL-33, IRAK4, and IRF5 — to overcome fundamental limitations of current adaptive-immune therapies. Its business model centers on generating transformative medicines for large, underserved autoimmune and inflammatory disease markets, including ulcerative colitis (2–3 million U.S. patients), systemic lupus erythematosus, and other interferonopathies, where it believes its mechanistic approach can yield deeper, more durable responses and reduced immunosuppressive risk. The company leverages two complementary modalities — oral small molecules and VHH-based protein therapeutics — supported by proprietary AI/ML platforms, structural biology expertise, and transcription factor reconstitution capabilities, enabling it to tackle historically challenging targets such as IRF5. As of March 31, 2026, it employed 100 full-time staff, 80 of whom were engaged in R&D, with ~60% holding Ph.D. or M.D. degrees — a highly specialized team aligned with its scientific strategy. Financially, Odyssey remains pre-revenue and deeply unprofitable: net losses totaled $148.6 million and $129.3 million for 2025 and 2024, respectively, and its accumulated deficit reached $568.1 million as of December 31, 2025. With $216.6 million in cash, cash equivalents and marketable securities at year-end 2025, management concluded it lacks sufficient liquidity to fund operations beyond the next 12 months — triggering a going concern qualification in its audited financial statements. The offering is therefore critical to bridge this gap and fund pivotal clinical milestones: OD-001’s randomized phase 2a combination trial with vedolizumab and phase 2b monotherapy trial are both expected to commence in second half of 2026, with topline induction readouts anticipated in second half of 2027. OD-002’s phase 1/2a trial is also slated for initiation in first half of 2027. The offering terms reflect typical IPO mechanics: shares will be listed on Nasdaq under ticker 'ODTX', with underwriters granted a 30-day option to purchase additional shares. While specific pricing and size are redacted, the document confirms the company intends to use proceeds to advance these trials, fund IND-enabling work for OD-002, and support broader pipeline expansion — including OD-003 (TNFR2 agonist) and OD-004 (TSLP/IL-33 bispecific), both in active lead optimization. Key risks are concrete and non-boilerplate: its open-label phase 2a design introduces bias concerns; its clinical sites span seven countries including Ukraine and Jordan, exposing it to geopolitical enrollment disruption; and its manufacturing and discovery activities rely on third parties in China and Ukraine — where trade tensions or war-related instability could impair timelines. Governance reflects strong investor influence: prior to the offering, board composition was governed by a voting agreement granting director nomination rights to investors including SR One, OrbiMed, Dimension Capital, Lightspeed, Jeito, and TPG — though those provisions terminate upon closing. Leadership features deep industry pedigree: CEO Glick and Chair Leiden have collectively driven over $200 billion in therapeutic value creation across HUMIRA®, TRIKAFTA®, and multiple acquired platforms. However, their concurrent roles — Glick as interim CEO of Charm Therapeutics and Leiden as managing member of Racing Beach Ventures — introduce real resource allocation constraints. Finally, Odyssey’s intellectual property strategy is still nascent: while it has filed patent applications covering OD-001 composition, crystalline forms, and combinations, none have issued yet, and its SLC15A4 portfolio comprises only provisional applications — meaning enforceable protection remains years away, heightening competitive vulnerability.